ID   SIR2_HUMAN              Reviewed;         389 AA.
AC   Q8IXJ6; A8K3V1; B2RB45; O95889; Q924Y7; Q9P0G8; Q9UNT0; Q9Y6E9; U5TP13;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   07-APR-2021, entry version 194.
DE   RecName: Full=NAD-dependent protein deacetylase sirtuin-2;
DE            EC=2.3.1.286 {ECO:0000269|PubMed:11483616, ECO:0000269|PubMed:11812793, ECO:0000269|PubMed:16648462, ECO:0000269|PubMed:18722353, ECO:0000269|PubMed:24177535, ECO:0000269|PubMed:24940000, ECO:0000269|PubMed:25672491};
DE   AltName: Full=Regulatory protein SIR2 homolog 2;
DE   AltName: Full=SIR2-like protein 2;
GN   Name=SIRT2; Synonyms=SIR2L, SIR2L2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND MUTAGENESIS
RP   OF HIS-187.
RC   TISSUE=Testis;
RX   PubMed=10381378; DOI=10.1006/bbrc.1999.0897;
RA   Frye R.A.;
RT   "Characterization of five human cDNAs with homology to the yeast SIR2 gene:
RT   Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-
RT   ribosyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 260:273-279(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10393250; DOI=10.1016/s0378-1119(99)00162-6;
RA   Afshar G., Murnane J.P.;
RT   "Characterization of a human gene with sequence homology to Saccharomyces
RT   cerevisiae SIR2.";
RL   Gene 234:161-168(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12065666; DOI=10.1046/j.1471-4159.2002.00847.x;
RA   De Smet C., Nishimori H., Furnari F.B., Boegler O., Huang H.-J.S.,
RA   Cavenee W.K.;
RT   "A novel seven transmembrane receptor induced during the early steps of
RT   astrocyte differentiation identified by differential expression.";
RL   J. Neurochem. 81:575-588(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), ALTERNATIVE SPLICING (ISOFORMS 1
RP   AND 2), FUNCTION IN DEACETYLATION (ISOFORMS 1 AND 2), CATALYTIC ACTIVITY,
RP   LACK OF DEACETYLATION (ISOFORM 5), INTERACTION WITH EP300 (ISOFORMS 1; 2
RP   AND 5), AND SUBCELLULAR LOCATION (ISOFORMS 1; 2 AND 5).
RX   PubMed=24177535; DOI=10.1016/j.jmb.2013.10.027;
RA   Rack J.G., Vanlinden M.R., Lutter T., Aasland R., Ziegler M.;
RT   "Constitutive nuclear localization of an alternatively spliced sirtuin-2
RT   isoform.";
RL   J. Mol. Biol. 426:1677-1691(2014).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Lennerz V., Fatho M., Gentilini C., Lifke A., Woelfel C., Woelfel T.;
RT   "Response of autologous T cells to a human melanoma is dominated by
RT   individual mutant antigens.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Adrenal gland;
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W.,
RA   Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J.,
RA   Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z.,
RA   Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis
RT   and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Lung;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 22-389 (ISOFORM 4).
RC   TISSUE=Brain;
RA   Mei G., Yu W., Gibbs R.A.;
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11226170; DOI=10.1093/emboj/20.1.197;
RA   Perrod S., Cockell M.M., Laroche T., Renauld H., Ducrest A.L., Bonnard C.,
RA   Gasser S.M.;
RT   "A cytosolic NAD-dependent deacetylase, Hst2p, can modulate nucleolar and
RT   telomeric silencing in yeast.";
RL   EMBO J. 20:197-209(2001).
RN   [12]
RP   INHIBITION BY SIRTINOL; A3 AND M15, CATALYTIC ACTIVITY, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11483616; DOI=10.1074/jbc.m106779200;
RA   Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., Schreiber S.L.;
RT   "Identification of a class of small molecule inhibitors of the sirtuin
RT   family of NAD-dependent deacetylases by phenotypic screening.";
RL   J. Biol. Chem. 276:38837-38843(2001).
RN   [13]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-187.
RX   PubMed=11812793; DOI=10.1074/jbc.m111830200;
RA   Borra M.T., O'Neill F.J., Jackson M.D., Marshall B.L., Verdin E.,
RA   Foltz K.R., Denu J.M.;
RT   "Conserved enzymatic production and biological effect of O-acetyl-ADP-
RT   ribose by silent information regulator 2-like NAD+-dependent
RT   deacetylases.";
RL   J. Biol. Chem. 277:12632-12641(2002).
RN   [14]
RP   FUNCTION IN DEACETYLATION OF TUBULIN, SUBCELLULAR LOCATION, INTERACTION
RP   WITH HDAC6, AND MUTAGENESIS OF ASN-168 AND HIS-187.
RX   PubMed=12620231; DOI=10.1016/s1097-2765(03)00038-8;
RA   North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E.;
RT   "The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin
RT   deacetylase.";
RL   Mol. Cell 11:437-444(2003).
RN   [15]
RP   FUNCTION AS REGULATOR OF CELL CYCLE PROGRESSION, SUBCELLULAR LOCATION,
RP   DEVELOPMENTAL STAGE, PHOSPHORYLATION, UBIQUITINATION, AND MUTAGENESIS OF
RP   HIS-187.
RX   PubMed=12697818; DOI=10.1128/mcb.23.9.3173-3185.2003;
RA   Dryden S.C., Nahhas F.A., Nowak J.E., Goustin A.-S., Tainsky M.A.;
RT   "Role for human SIRT2 NAD-dependent deacetylase activity in control of
RT   mitotic exit in the cell cycle.";
RL   Mol. Cell. Biol. 23:3173-3185(2003).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=12963026; DOI=10.1016/j.bbrc.2003.08.029;
RA   Hiratsuka M., Inoue T., Toda T., Kimura N., Shirayoshi Y., Kamitani H.,
RA   Watanabe T., Ohama E., Tahimic C.G.T., Kurimasa A., Oshimura M.;
RT   "Proteomics-based identification of differentially expressed genes in human
RT   gliomas: down-regulation of SIRT2 gene.";
RL   Biochem. Biophys. Res. Commun. 309:558-566(2003).
RN   [17]
RP   INTERACTION WITH HOXA10.
RX   PubMed=15213244; DOI=10.1093/jb/mvh084;
RA   Bae N.S., Swanson M.J., Vassilev A., Howard B.H.;
RT   "Human histone deacetylase SIRT2 interacts with the homeobox transcription
RT   factor HOXA10.";
RL   J. Biochem. 135:695-700(2004).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16079181; DOI=10.1091/mbc.e05-01-0033;
RA   Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I.;
RT   "Evolutionarily conserved and nonconserved cellular localizations and
RT   functions of human SIRT proteins.";
RL   Mol. Biol. Cell 16:4623-4635(2005).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [20]
RP   FUNCTION IN DEACETYLATION OF HISTONE H4 AND H3, CATALYTIC ACTIVITY,
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=16648462; DOI=10.1101/gad.1412706;
RA   Vaquero A., Scher M.B., Lee D.H., Sutton A., Cheng H.L., Alt F.W.,
RA   Serrano L., Sternglanz R., Reinberg D.;
RT   "SirT2 is a histone deacetylase with preference for histone H4 Lys 16
RT   during mitosis.";
RL   Genes Dev. 20:1256-1261(2006).
RN   [21]
RP   FUNCTION AS REGULATOR IN CELL CYCLE PROGRESSION, PHOSPHORYLATION AT SER-368
RP   BY CDK1, DEPHOSPHORYLATION AT SER-368 BY CDC14A AND CDC14B, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF HIS-187 AND SER-368.
RX   PubMed=17488717; DOI=10.1074/jbc.m702990200;
RA   North B.J., Verdin E.;
RT   "Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent
RT   phosphorylation.";
RL   J. Biol. Chem. 282:19546-19555(2007).
RN   [22]
RP   INTERACTION WITH HDAC6 (ISOFORMS 1 AND 2), PHOSPHORYLATION AT SER-372 AND
RP   SER-368, UBIQUITINATION, AND MUTAGENESIS OF SER-53; SER-98; SER-100;
RP   HIS-187; SER-279; THR-280; SER-311; TYR-315; SER-364; SER-368 AND SER-372.
RX   PubMed=17516032; DOI=10.1007/s11010-007-9478-6;
RA   Nahhas F., Dryden S.C., Abrams J., Tainsky M.A.;
RT   "Mutations in SIRT2 deacetylase which regulate enzymatic activity but not
RT   its interaction with HDAC6 and tubulin.";
RL   Mol. Cell. Biochem. 303:221-230(2007).
RN   [23]
RP   FUNCTION IN AXONAL DEGENERATION.
RX   PubMed=17574768; DOI=10.1016/j.neuroscience.2007.04.059;
RA   Suzuki K., Koike T.;
RT   "Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance
RT   to axonal degeneration in slow Wallerian degeneration mice: a crucial role
RT   of tubulin deacetylation.";
RL   Neuroscience 147:599-612(2007).
RN   [24]
RP   FUNCTION AS REGULATOR OF MITOTIC CELL CYCLE CHECKPOINT, SUBCELLULAR
RP   LOCATION, NUCLEOCYTOPLASMIC SHUTTLING, INDUCTION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF GLN-167; ASN-168 AND HIS-187.
RX   PubMed=16909107; DOI=10.1038/sj.onc.1209857;
RA   Inoue T., Hiratsuka M., Osaki M., Yamada H., Kishimoto I., Yamaguchi S.,
RA   Nakano S., Katoh M., Ito H., Oshimura M.;
RT   "SIRT2, a tubulin deacetylase, acts to block the entry to chromosome
RT   condensation in response to mitotic stress.";
RL   Oncogene 26:945-957(2007).
RN   [25]
RP   FUNCTION AS REGULATOR IN CELL CYCLE PROGRESSION, INTERACTION WITH AURKA,
RP   SUBCELLULAR LOCATION, NUCLEOCYTOPLASMIC SHUTTLING, AND MUTAGENESIS OF
RP   HIS-187.
RX   PubMed=17726514; DOI=10.1371/journal.pone.0000784;
RA   North B.J., Verdin E.;
RT   "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during
RT   mitosis.";
RL   PLoS ONE 2:E784-E784(2007).
RN   [26]
RP   FUNCTION IN DEACETYLATION OF TP53, FUNCTION IN REGULATION OF TP53, AND
RP   INTERACTION WITH YWHAB AND YWHAG.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of
RT   p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [27]
RP   INTERACTION WITH EP300, ACETYLATION BY EP300, ACTIVITY REGULATION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=18722353; DOI=10.1016/j.bbrc.2008.08.042;
RA   Han Y., Jin Y.H., Kim Y.J., Kang B.Y., Choi H.J., Kim D.W., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Acetylation of Sirt2 by p300 attenuates its deacetylase activity.";
RL   Biochem. Biophys. Res. Commun. 375:576-580(2008).
RN   [28]
RP   FUNCTION IN STRESS RESPONSE, AND INDUCTION BY STRESS.
RX   PubMed=18640115; DOI=10.1016/j.febslet.2008.07.016;
RA   Lynn E.G., McLeod C.J., Gordon J.P., Bao J., Sack M.N.;
RT   "SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via
RT   regulation of 14-3-3 zeta and BAD in H9c2 cells.";
RL   FEBS Lett. 582:2857-2862(2008).
RN   [29]
RP   FUNCTION IN DEACETYLATION OF ALPHA-TUBULIN AND HISTONE, FUNCTION IN
RP   REGULATION OF CELL MOTILITY, INTERACTION WITH CDK5R1; CDK5 AND CYCLIN
RP   E-CDK2 COMPLEX, PHOSPHORYLATION AT SER-368 BY CDK2 AND CDK5, AND
RP   MUTAGENESIS OF SER-368.
RX   PubMed=18332217; DOI=10.1083/jcb.200707126;
RA   Pandithage R., Lilischkis R., Harting K., Wolf A., Jedamzik B.,
RA   Luscher-Firzlaff J., Vervoorts J., Lasonder E., Kremmer E., Knoll B.,
RA   Luscher B.;
RT   "The regulation of SIRT2 function by cyclin-dependent kinases affects cell
RT   motility.";
RL   J. Cell Biol. 180:915-929(2008).
RN   [30]
RP   FUNCTION IN DEACETYLATION OF EP300 AND ALPHA-TUBULIN, FUNCTION IN
RP   REGULATION OF EP300, AND SUBCELLULAR LOCATION.
RX   PubMed=18995842; DOI=10.1016/j.molcel.2008.09.018;
RA   Black J.C., Mosley A., Kitada T., Washburn M., Carey M.;
RT   "The SIRT2 deacetylase regulates autoacetylation of p300.";
RL   Mol. Cell 32:449-455(2008).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [33]
RP   FUNCTION AS REGULATOR OF MITOTIC CELL CYCLE CHECKPOINT.
RX   PubMed=19282667; DOI=10.4161/cc.8.8.8245;
RA   Inoue T., Nakayama Y., Yamada H., Li Y.C., Yamaguchi S., Osaki M.,
RA   Kurimasa A., Hiratsuka M., Katoh M., Oshimura M.;
RT   "SIRT2 downregulation confers resistance to microtubule inhibitors by
RT   prolonging chronic mitotic arrest.";
RL   Cell Cycle 8:1279-1291(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   FUNCTION IN DEACETYLATION OF HISTONE H3.
RX   PubMed=20587414; DOI=10.1074/jbc.m110.149393;
RA   Vempati R.K., Jayani R.S., Notani D., Sengupta A., Galande S., Haldar D.;
RT   "p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage
RT   response in mammals.";
RL   J. Biol. Chem. 285:28553-28564(2010).
RN   [36]
RP   FUNCTION IN DEACETYLATION OF RELA, FUNCTION IN REGULATION OF RELA ACTIVITY,
RP   INTERACTION WITH RELA, AND SUBCELLULAR LOCATION.
RX   PubMed=21081649; DOI=10.1242/jcs.073783;
RA   Rothgiesser K.M., Erener S., Waibel S., Luscher B., Hottiger M.O.;
RT   "SIRT2 regulates NF-kappaB dependent gene expression through deacetylation
RT   of p65 Lys310.";
RL   J. Cell Sci. 123:4251-4258(2010).
RN   [37]
RP   FUNCTION IN DEACETYLATION OF FOXO1, FUNCTION IN AUTOPHAGY, AND INTERACTION
RP   WITH FOXO1.
RX   PubMed=20543840; DOI=10.1038/ncb2069;
RA   Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., Wang D., Feng J.,
RA   Yu L., Zhu W.G.;
RT   "Cytosolic FoxO1 is essential for the induction of autophagy and tumour
RT   suppressor activity.";
RL   Nat. Cell Biol. 12:665-675(2010).
RN   [38]
RP   FUNCTION IN DEACETYLATION OF CDC20 AND FZR1, FUNCTION AS A TUMOR
RP   SUPPRESSOR, TISSUE SPECIFICITY, AND MUTAGENESIS OF HIS-187.
RX   PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004;
RA   Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C.,
RA   Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I.,
RA   Gius D., Deng C.X.;
RT   "SIRT2 maintains genome integrity and suppresses tumorigenesis through
RT   regulating APC/C activity.";
RL   Cancer Cell 20:487-499(2011).
RN   [39]
RP   TISSUE SPECIFICITY.
RX   PubMed=21791548; DOI=10.1093/hmg/ddr326;
RA   Maxwell M.M., Tomkinson E.M., Nobles J., Wizeman J.W., Amore A.M.,
RA   Quinti L., Chopra V., Hersch S.M., Kazantsev A.G.;
RT   "The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that
RT   accumulates in the aging CNS.";
RL   Hum. Mol. Genet. 20:3986-3996(2011).
RN   [40]
RP   FUNCTION IN DEACETYLATION OF PCK1, POSSIBLE FUNCTION IN REGULATION OF BLOOD
RP   GLUCOSE HOMEOSTASIS, AND INDUCTION BY GLUCOSE.
RX   PubMed=21726808; DOI=10.1016/j.molcel.2011.04.028;
RA   Jiang W., Wang S., Xiao M., Lin Y., Zhou L., Lei Q., Xiong Y., Guan K.L.,
RA   Zhao S.;
RT   "Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via
RT   recruiting the UBR5 ubiquitin ligase.";
RL   Mol. Cell 43:33-44(2011).
RN   [41]
RP   FUNCTION IN DEACETYLATION OF PARD3, AND INTERACTION WITH PARD3.
RX   PubMed=21949390; DOI=10.1073/pnas.1104969108;
RA   Beirowski B., Gustin J., Armour S.M., Yamamoto H., Viader A., North B.J.,
RA   Michan S., Baloh R.H., Golden J.P., Schmidt R.E., Sinclair D.A., Auwerx J.,
RA   Milbrandt J.;
RT   "Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through
RT   polarity protein Par-3/atypical protein kinase C (aPKC) signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:E952-961(2011).
RN   [42]
RP   FUNCTION IN DEACETYLATION OF EIF5A.
RX   PubMed=22771473; DOI=10.1016/j.febslet.2012.06.042;
RA   Ishfaq M., Maeta K., Maeda S., Natsume T., Ito A., Yoshida M.;
RT   "Acetylation regulates subcellular localization of eukaryotic translation
RT   initiation factor 5A (eIF5A).";
RL   FEBS Lett. 586:3236-3241(2012).
RN   [43]
RP   FUNCTION IN AUTOPHAGY, AND SUBCELLULAR LOCATION.
RX   PubMed=22819792; DOI=10.1016/j.neuint.2012.07.010;
RA   Gal J., Bang Y., Choi H.J.;
RT   "SIRT2 interferes with autophagy-mediated degradation of protein aggregates
RT   in neuronal cells under proteasome inhibition.";
RL   Neurochem. Int. 61:992-1000(2012).
RN   [44]
RP   REVIEW, AND FUNCTION AS A TUMOR SUPPRESSOR.
RX   PubMed=22943040;
RA   Park S.H., Zhu Y., Ozden O., Kim H.S., Jiang H., Deng C.X., Gius D.,
RA   Vassilopoulos A.;
RT   "SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle
RT   signaling, and carcinogenesis.";
RL   Transl. Cancer Res. 1:15-21(2012).
RN   [45]
RP   INTERACTION WITH MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=23806683; DOI=10.1016/j.bbrc.2013.06.053;
RA   Choi Y.H., Kim H., Lee S.H., Jin Y.H., Lee K.Y.;
RT   "ERK1/2 regulates SIRT2 deacetylase activity.";
RL   Biochem. Biophys. Res. Commun. 437:245-249(2013).
RN   [46]
RP   FUNCTION IN DEACETYLATION OF HISTONE H4K16 AND KMT5A, FUNCTION IN
RP   REGULATION OF KMT5A ACTIVITY; H4K20 METHYLATION; CELL CYCLE PROGRESSION AND
RP   GENOMIC STABILITY, INTERACTION WITH KMT5A, SUBCELLULAR LOCATION, AND MASS
RP   SPECTROMETRY.
RX   PubMed=23468428; DOI=10.1101/gad.211342.112;
RA   Serrano L., Martinez-Redondo P., Marazuela-Duque A., Vazquez B.N.,
RA   Dooley S.J., Voigt P., Beck D.B., Kane-Goldsmith N., Tong Q., Rabanal R.M.,
RA   Fondevila D., Munoz P., Kruger M., Tischfield J.A., Vaquero A.;
RT   "The tumor suppressor SirT2 regulates cell cycle progression and genome
RT   stability by modulating the mitotic deposition of H4K20 methylation.";
RL   Genes Dev. 27:639-653(2013).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-368, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   FUNCTION.
RX   PubMed=23932781; DOI=10.1016/j.molcel.2013.07.002;
RA   Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., Xiong Y., Lei Q.Y.;
RT   "Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and
RT   tumor growth.";
RL   Mol. Cell 51:506-518(2013).
RN   [49]
RP   FUNCTION IN DEACETYLATION OF HISTONE H3K18, FUNCTION IN LISTERIA INFECTION,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-168.
RX   PubMed=23908241; DOI=10.1126/science.1238858;
RA   Eskandarian H.A., Impens F., Nahori M.A., Soubigou G., Coppee J.Y.,
RA   Cossart P., Hamon M.A.;
RT   "A role for SIRT2-dependent histone H3K18 deacetylation in bacterial
RT   infection.";
RL   Science 341:1238858-1238858(2013).
RN   [50]
RP   FUNCTION IN HISTONE H4 DEACETYLATION, FUNCTION IN REGULATION OF VEGFA
RP   EXPRESSION AND ANGIOGENESIS, CATALYTIC ACTIVITY, AND INTERACTION WITH
RP   SARS1.
RX   PubMed=24940000; DOI=10.7554/elife.02349;
RA   Shi Y., Xu X., Zhang Q., Fu G., Mo Z., Wang G.S., Kishi S., Yang X.L.;
RT   "tRNA synthetase counteracts c-Myc to develop functional vasculature.";
RL   Elife 3:E02349-E02349(2014).
RN   [51]
RP   FUNCTION IN DEACETYLATION OF G6PD, FUNCTION IN REGULATION OF G6PD ACTIVITY,
RP   INTERACTION WITH G6PD, AND MUTAGENESIS OF ASN-168.
RX   PubMed=24769394; DOI=10.1002/embj.201387224;
RA   Wang Y.P., Zhou L.S., Zhao Y.Z., Wang S.W., Chen L.L., Liu L.X., Ling Z.Q.,
RA   Hu F.J., Sun Y.P., Zhang J.Y., Yang C., Yang Y., Xiong Y., Guan K.L.,
RA   Ye D.;
RT   "Regulation of G6PD acetylation by KAT9/SIRT2 modulates NADPH homeostasis
RT   and cell survival during oxidative stress.";
RL   EMBO J. 33:1304-1320(2014).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25 AND SER-27, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [53]
RP   FUNCTION IN DEACETYLATION OF HIF1A, FUNCTION IN REGULATION OF HIF1A
RP   STABILITY, INTERACTION WITH HIF1A, MUTAGENESIS OF HIS-187, SUBCELLULAR
RP   LOCATION, AND MASS SPECTROMETRY.
RX   PubMed=24681946; DOI=10.1038/onc.2014.76;
RA   Seo K.S., Park J.H., Heo J.Y., Jing K., Han J., Min K.N., Kim C., Koh G.Y.,
RA   Lim K., Kang G.Y., Uee Lee J., Yim Y.H., Shong M., Kwak T.H., Kweon G.R.;
RT   "SIRT2 regulates tumour hypoxia response by promoting HIF-1alpha
RT   hydroxylation.";
RL   Oncogene 34:1354-1362(2015).
RN   [54]
RP   INTERACTION WITH BEX4, AND MUTAGENESIS OF HIS-187.
RX   PubMed=27512957; DOI=10.1038/cddis.2016.240;
RA   Lee J.K., Lee J., Go H., Lee C.G., Kim S., Kim H.S., Cho H., Choi K.S.,
RA   Ha G.H., Lee C.W.;
RT   "Oncogenic microtubule hyperacetylation through BEX4-mediated sirtuin 2
RT   inhibition.";
RL   Cell Death Dis. 7:E2336-E2336(2016).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 34-356 IN COMPLEX WITH ZINC, AND
RP   MUTAGENESIS OF ARG-97; GLN-167; ASN-168; ASP-170 AND HIS-187.
RX   PubMed=11427894; DOI=10.1038/89668;
RA   Finnin M.S., Donigian J.R., Pavletich N.P.;
RT   "Structure of the histone deacetylase SIRT2.";
RL   Nat. Struct. Biol. 8:621-625(2001).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS) OF 34-356 IN COMPLEX WITH NAD ANALOG
RP   AND ZINC.
RX   PubMed=23454361; DOI=10.1016/j.jsb.2013.02.012;
RA   Moniot S., Schutkowski M., Steegborn C.;
RT   "Crystal structure analysis of human Sirt2 and its ADP-ribose complex.";
RL   J. Struct. Biol. 182:136-143(2013).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 55-356 IN COMPLEX WITH PEPTIDE
RP   INHIBITOR AND ZINC, ACTIVITY REGULATION, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF GLU-116; GLU-120; PHE-244; GLN-265; SER-271 AND ASP-294.
RX   PubMed=24389023; DOI=10.1016/j.str.2013.12.001;
RA   Yamagata K., Goto Y., Nishimasu H., Morimoto J., Ishitani R., Dohmae N.,
RA   Takeda N., Nagai R., Komuro I., Suga H., Nureki O.;
RT   "Structural basis for potent inhibition of SIRT2 deacetylase by a
RT   macrocyclic peptide inducing dynamic structural change.";
RL   Structure 22:345-352(2014).
RN   [58] {ECO:0007744|PDB:4RMG, ECO:0007744|PDB:4RMH, ECO:0007744|PDB:4RMI, ECO:0007744|PDB:4RMJ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 56-356 IN COMPLEX WITH NAD AND
RP   ZINC, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=25672491; DOI=10.1038/ncomms7263;
RA   Rumpf T., Schiedel M., Karaman B., Roessler C., North B.J., Lehotzky A.,
RA   Olah J., Ladwein K.I., Schmidtkunz K., Gajer M., Pannek M., Steegborn C.,
RA   Sinclair D.A., Gerhardt S., Ovadi J., Schutkowski M., Sippl W., Einsle O.,
RA   Jung M.;
RT   "Selective Sirt2 inhibition by ligand-induced rearrangement of the active
RT   site.";
RL   Nat. Commun. 6:6263-6263(2015).
CC   -!- FUNCTION: NAD-dependent protein deacetylase, which deacetylates
CC       internal lysines on histone and alpha-tubulin as well as many other
CC       proteins such as key transcription factors (PubMed:24177535,
CC       PubMed:12620231, PubMed:16648462, PubMed:18249187, PubMed:18332217,
CC       PubMed:18995842, PubMed:20587414, PubMed:21081649, PubMed:20543840,
CC       PubMed:22014574, PubMed:21726808, PubMed:21949390, PubMed:22771473,
CC       PubMed:23468428, PubMed:23908241, PubMed:24940000, PubMed:24769394,
CC       PubMed:24681946). Participates in the modulation of multiple and
CC       diverse biological processes such as cell cycle control, genomic
CC       integrity, microtubule dynamics, cell differentiation, metabolic
CC       networks, and autophagy. Plays a major role in the control of cell
CC       cycle progression and genomic stability. Functions in the antephase
CC       checkpoint preventing precocious mitotic entry in response to
CC       microtubule stress agents, and hence allowing proper inheritance of
CC       chromosomes. Positively regulates the anaphase promoting
CC       complex/cyclosome (APC/C) ubiquitin ligase complex activity by
CC       deacetylating CDC20 and FZR1, then allowing progression through
CC       mitosis. Associates both with chromatin at transcriptional start sites
CC       (TSSs) and enhancers of active genes. Plays a role in cell cycle and
CC       chromatin compaction through epigenetic modulation of the regulation of
CC       histone H4 'Lys-20' methylation (H4K20me1) during early mitosis.
CC       Specifically deacetylates histone H4 at 'Lys-16' (H4K16ac) between the
CC       G2/M transition and metaphase enabling H4K20me1 deposition by KMT5A
CC       leading to ulterior levels of H4K20me2 and H4K20me3 deposition
CC       throughout cell cycle, and mitotic S-phase progression
CC       (PubMed:23468428). Deacetylates KMT5A modulating KMT5A chromatin
CC       localization during the mitotic stress response (PubMed:23468428).
CC       Deacetylates also histone H3 at 'Lys-57' (H3K56ac) during the mitotic
CC       G2/M transition. Upon bacterium Listeria monocytogenes infection,
CC       deacetylates 'Lys-18' of histone H3 in a receptor tyrosine kinase
CC       MET- and PI3K/Akt-dependent manner, thereby inhibiting transcriptional
CC       activity and promoting late stages of listeria infection
CC       (PubMed:23908241). During oocyte meiosis progression, may deacetylate
CC       histone H4 at 'Lys-16' (H4K16ac) and alpha-tubulin, regulating spindle
CC       assembly and chromosome alignment by influencing microtubule dynamics
CC       and kinetochore function. Deacetylates histone H4 at 'Lys-16' (H4K16ac)
CC       at the VEGFA promoter and thereby contributes to regulate expression of
CC       VEGFA, a key regulator of angiogenesis (PubMed:24940000). Deacetylates
CC       alpha-tubulin at 'Lys-40' and hence controls neuronal motility,
CC       oligodendroglial cell arbor projection processes and proliferation of
CC       non-neuronal cells. Phosphorylation at Ser-368 by a G1/S-specific
CC       cyclin E-CDK2 complex inactivates SIRT2-mediated alpha-tubulin
CC       deacetylation, negatively regulating cell adhesion, cell migration and
CC       neurite outgrowth during neuronal differentiation. Deacetylates PARD3
CC       and participates in the regulation of Schwann cell peripheral
CC       myelination formation during early postnatal development and during
CC       postinjury remyelination. Involved in several cellular metabolic
CC       pathways. Plays a role in the regulation of blood glucose homeostasis
CC       by deacetylating and stabilizing phosphoenolpyruvate carboxykinase PCK1
CC       activity in response to low nutrient availability. Acts as a key
CC       regulator in the pentose phosphate pathway (PPP) by deacetylating and
CC       activating the glucose-6-phosphate G6PD enzyme, and therefore,
CC       stimulates the production of cytosolic NADPH to counteract oxidative
CC       damage. Maintains energy homeostasis in response to nutrient
CC       deprivation as well as energy expenditure by inhibiting adipogenesis
CC       and promoting lipolysis. Attenuates adipocyte differentiation by
CC       deacetylating and promoting FOXO1 interaction to PPARG and subsequent
CC       repression of PPARG-dependent transcriptional activity. Plays a role in
CC       the regulation of lysosome-mediated degradation of protein aggregates
CC       by autophagy in neuronal cells. Deacetylates FOXO1 in response to
CC       oxidative stress or serum deprivation, thereby negatively regulating
CC       FOXO1-mediated autophagy (PubMed:20543840). Deacetylates a broad range
CC       of transcription factors and co-regulators regulating target gene
CC       expression. Deacetylates transcriptional factor FOXO3 stimulating the
CC       ubiquitin ligase SCF(SKP2)-mediated FOXO3 ubiquitination and
CC       degradation (By similarity). Deacetylates HIF1A and therefore promotes
CC       HIF1A degradation and inhibition of HIF1A transcriptional activity in
CC       tumor cells in response to hypoxia (PubMed:24681946). Deacetylates RELA
CC       in the cytoplasm inhibiting NF-kappaB-dependent transcription
CC       activation upon TNF-alpha stimulation. Inhibits transcriptional
CC       activation by deacetylating p53/TP53 and EP300 (PubMed:18249187).
CC       Deacetylates also EIF5A (PubMed:22771473). Functions as a negative
CC       regulator on oxidative stress-tolerance in response to anoxia-
CC       reoxygenation conditions. Plays a role as tumor suppressor
CC       (PubMed:22014574). {ECO:0000250|UniProtKB:Q8VDQ8,
CC       ECO:0000269|PubMed:12620231, ECO:0000269|PubMed:12697818,
CC       ECO:0000269|PubMed:16648462, ECO:0000269|PubMed:16909107,
CC       ECO:0000269|PubMed:17488717, ECO:0000269|PubMed:17574768,
CC       ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:18249187,
CC       ECO:0000269|PubMed:18332217, ECO:0000269|PubMed:18640115,
CC       ECO:0000269|PubMed:18722353, ECO:0000269|PubMed:18995842,
CC       ECO:0000269|PubMed:19282667, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:20587414, ECO:0000269|PubMed:21081649,
CC       ECO:0000269|PubMed:21726808, ECO:0000269|PubMed:21949390,
CC       ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:22771473,
CC       ECO:0000269|PubMed:22819792, ECO:0000269|PubMed:23468428,
CC       ECO:0000269|PubMed:23908241, ECO:0000269|PubMed:23932781,
CC       ECO:0000269|PubMed:24177535, ECO:0000269|PubMed:24681946,
CC       ECO:0000269|PubMed:24769394, ECO:0000269|PubMed:24940000}.
CC   -!- FUNCTION: [Isoform 1]: Deacetylates EP300, alpha-tubulin and histone H3
CC       and H4. {ECO:0000269|PubMed:24177535}.
CC   -!- FUNCTION: [Isoform 2]: Deacetylates EP300, alpha-tubulin and histone H3
CC       and H4. {ECO:0000269|PubMed:24177535}.
CC   -!- FUNCTION: [Isoform 5]: Lacks deacetylation activity.
CC       {ECO:0000269|PubMed:24177535}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N(6)-acetyl-L-lysyl-[protein] + NAD(+) = 2''-O-acetyl-
CC         ADP-D-ribose + L-lysyl-[protein] + nicotinamide;
CC         Xref=Rhea:RHEA:43636, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:10731,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:61930, ChEBI:CHEBI:83767;
CC         EC=2.3.1.286; Evidence={ECO:0000255|PROSITE-ProRule:PRU00236,
CC         ECO:0000269|PubMed:11483616, ECO:0000269|PubMed:11812793,
CC         ECO:0000269|PubMed:16648462, ECO:0000269|PubMed:18722353,
CC         ECO:0000269|PubMed:24177535, ECO:0000269|PubMed:24389023,
CC         ECO:0000269|PubMed:24940000, ECO:0000269|PubMed:25672491};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:25672491};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:25672491};
CC   -!- ACTIVITY REGULATION: Inhibited by Sirtinol, A3 and M15 small molecules
CC       (PubMed:11483616). Inhibited by nicotinamide. Inhibited by a
CC       macrocyclic peptide inhibitor S2iL5 (PubMed:24389023). Inhibited by
CC       EP300-induced acetylation (PubMed:18722353).
CC       {ECO:0000269|PubMed:11483616, ECO:0000269|PubMed:18722353,
CC       ECO:0000269|PubMed:24389023}.
CC   -!- SUBUNIT: Interacts with CDC20, FOXO3 and FZR1. Associates with
CC       microtubules in primary cortical mature neurons (By similarity).
CC       Homotrimer. Isoform 1 and isoform 2 interact (via both phosphorylated,
CC       unphosphorylated, active or inactive forms) with HDAC6; the interaction
CC       is necessary for the complex to interact with alpha-tubulin, suggesting
CC       that these proteins belong to a large complex that deacetylates the
CC       cytoskeleton. Interacts with FOXO1; the interaction is disrupted upon
CC       serum-starvation or oxidative stress, leading to increased level of
CC       acetylated FOXO1 and induction of autophagy. Interacts with RELA; the
CC       interaction occurs in the cytoplasm and is increased in a TNF-alpha-
CC       dependent manner. Interacts with HOXA10; the interaction is direct.
CC       Interacts with YWHAB and YWHAG; the interactions occur in a AKT-
CC       dependent manner and increase SIRT2-dependent TP53 deacetylation.
CC       Interacts with MAPK1/ERK2 and MAPK3/ERK1; the interactions increase
CC       SIRT2 stability and deacetylation activity. Interacts (phosphorylated
CC       form) with KMT5A isoform 2; the interaction is direct, stimulates
CC       KMT5A-mediated methyltransferase activity on histone at 'Lys-20'
CC       (H4K20me1) and is increased in a H(2)O(2)-induced oxidative stress-
CC       dependent manner. Interacts with G6PD; the interaction is enhanced by
CC       H(2)O(2) treatment. Interacts with a G1/S-specific cyclin E-CDK2
CC       complex. Interacts with AURKA, CDK5R1 (p35 form) and CDK5 and HIF1A.
CC       Isoform 1, isoform 2 and isoform 5 interact (via C-terminus region)
CC       with EP300 (PubMed:24177535). Interacts with the tRNA ligase SARS1;
CC       recruited to the VEGFA promoter via interaction with SARS1
CC       (PubMed:24940000). Interacts with BEX4; negatively regulates alpha-
CC       tubulin deacetylation by SIRT2 (PubMed:27512957). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q8VDQ8, ECO:0000269|PubMed:11427894,
CC       ECO:0000269|PubMed:12620231, ECO:0000269|PubMed:15213244,
CC       ECO:0000269|PubMed:16648462, ECO:0000269|PubMed:17726514,
CC       ECO:0000269|PubMed:18249187, ECO:0000269|PubMed:18332217,
CC       ECO:0000269|PubMed:18722353, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:21081649, ECO:0000269|PubMed:21949390,
CC       ECO:0000269|PubMed:23454361, ECO:0000269|PubMed:23468428,
CC       ECO:0000269|PubMed:23806683, ECO:0000269|PubMed:24177535,
CC       ECO:0000269|PubMed:24389023, ECO:0000269|PubMed:24681946,
CC       ECO:0000269|PubMed:24769394, ECO:0000269|PubMed:24940000,
CC       ECO:0000269|PubMed:27512957}.
CC   -!- INTERACTION:
CC       Q8IXJ6; O60566: BUB1B; NbExp=3; IntAct=EBI-477232, EBI-1001438;
CC       Q8IXJ6; O60729: CDC14B; NbExp=2; IntAct=EBI-477232, EBI-970231;
CC       Q8IXJ6; P11413: G6PD; NbExp=3; IntAct=EBI-477232, EBI-4289891;
CC       Q8IXJ6; Q92831: KAT2B; NbExp=4; IntAct=EBI-477232, EBI-477430;
CC       Q8IXJ6; Q04206: RELA; NbExp=2; IntAct=EBI-477232, EBI-73886;
CC       Q8IXJ6; Q9BYB0: SHANK3; NbExp=2; IntAct=EBI-477232, EBI-1752330;
CC       Q8IXJ6-2; Q12834: CDC20; NbExp=2; IntAct=EBI-5240785, EBI-367462;
CC       Q8IXJ6-2; Q9UM11: FZR1; NbExp=2; IntAct=EBI-5240785, EBI-724997;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, perinuclear region.
CC       Cytoplasm. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome, centriole. Cytoplasm,
CC       cytoskeleton, spindle. Midbody. Chromosome. Perikaryon {ECO:0000250}.
CC       Cell projection {ECO:0000250}. Cell projection, growth cone
CC       {ECO:0000250}. Myelin membrane {ECO:0000250}. Note=Deacetylates FOXO3
CC       in the cytoplasm. Colocalizes with PLP1 in internodal regions, at
CC       paranodal axoglial junction and Schmidt-Lanterman incisures of myelin
CC       sheat. Colocalizes with CDK5R1 in the perikaryon, neurites and growth
CC       cone of hippocampal neurons. Colocalizes with alpha-tubulin in neuronal
CC       growth cone. Localizes in the cytoplasm and nucleus of germinal vesicle
CC       (GV) stage oocytes. Colocalizes with alpha-tubulin on the meiotic
CC       spindle as the oocytes enter into metaphase, and also during meiotic
CC       anaphase and telophase, especially with the midbody. Colocalizes with
CC       PARD3 in internodal region of axons. Colocalizes with acetylated alpha-
CC       tubulin in cell projection processes during primary oligodendrocyte
CC       precursor (OLP) differentiation (By similarity). Localizes in the
CC       cytoplasm during most of the cell cycle except in the G2/M transition
CC       and during mitosis, where it is localized in association with chromatin
CC       and induces deacetylation of histone at 'Lys-16' (H4K16ac). Colocalizes
CC       with KMT5A at mitotic foci. Colocalizes with CDK1 at centrosome during
CC       prophase and splindle fibers during metaphase. Colocalizes with Aurora
CC       kinase AURKA at centrosome during early prophase and in the centrioles
CC       and growing mitotic spindle throughout metaphase. Colocalizes with
CC       Aurora kinase AURKB during cytokinesis with the midbody. Colocalizes
CC       with microtubules. Detected in perinuclear foci that may be aggresomes
CC       containing misfolded, ubiquitinated proteins. Shuttles between the
CC       cytoplasm and the nucleus through the CRM1 export pathway. Colocalizes
CC       with EP300 in the nucleus. Translocates to the nucleus and chromatin
CC       upon bacterium Listeria monocytogenes infection in interphase cells.
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000269|PubMed:24177535}. Nucleus {ECO:0000269|PubMed:24177535}.
CC       Note=Predominantly localized in the cytoplasmic.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:24177535}. Nucleus {ECO:0000269|PubMed:24177535}.
CC       Note=Predominantly localized in the cytoplasmic.
CC   -!- SUBCELLULAR LOCATION: [Isoform 5]: Cytoplasm
CC       {ECO:0000269|PubMed:24177535}. Nucleus {ECO:0000269|PubMed:24177535}.
CC       Note=Predominantly localized in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q8IXJ6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IXJ6-2; Sequence=VSP_008724;
CC       Name=3;
CC         IsoId=Q8IXJ6-3; Sequence=VSP_008726;
CC       Name=4;
CC         IsoId=Q8IXJ6-4; Sequence=VSP_008727, VSP_008728;
CC       Name=5;
CC         IsoId=Q8IXJ6-5; Sequence=VSP_055328;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in heart, liver and skeletal
CC       muscle, weakly expressed in the cortex. Isoform 2 is strongly expressed
CC       in the cortex, weakly expressed in heart and liver. Weakly expressed in
CC       several malignancies including breast, liver, brain, kidney and
CC       prostate cancers compared to normal tissues. Weakly expressed in glioma
CC       cell lines compared to normal brain tissues (at protein level). Widely
CC       expressed. Highly expressed in heart, brain and skeletal muscle, while
CC       it is weakly expressed in placenta and lung. Down-regulated in many
CC       gliomas suggesting that it may act as a tumor suppressor gene in human
CC       gliomas possibly through the regulation of microtubule network.
CC       {ECO:0000269|PubMed:10381378, ECO:0000269|PubMed:10393250,
CC       ECO:0000269|PubMed:12963026, ECO:0000269|PubMed:16909107,
CC       ECO:0000269|PubMed:21791548, ECO:0000269|PubMed:22014574}.
CC   -!- DEVELOPMENTAL STAGE: Peaks during mitosis. After mitosis, it is
CC       probably degraded by the 26S proteasome. {ECO:0000269|PubMed:12697818}.
CC   -!- INDUCTION: Up-regulated in response to low levels of glucose and
CC       anoxia-reoxygenation stress. Up-regulated by trichostatin A. Down-
CC       regulated in response to high levels of glucose. Down-regulated by
CC       histone deacetylation in several tumors. {ECO:0000269|PubMed:16909107,
CC       ECO:0000269|PubMed:18640115, ECO:0000269|PubMed:21726808}.
CC   -!- PTM: Phosphorylated at phosphoserine and phosphothreonine.
CC       Phosphorylated at Ser-368 by a mitotic kinase CDK1/cyclin B at the G2/M
CC       transition; phosphorylation regulates the delay in cell-cycle
CC       progression. Phosphorylated at Ser-368 by a mitotic kinase G1/S-
CC       specific cyclin E/Cdk2 complex; phosphorylation inactivates SIRT2-
CC       mediated alpha-tubulin deacetylation and thereby negatively regulates
CC       cell adhesion, cell migration and neurite outgrowth during neuronal
CC       differentiation. Phosphorylated by cyclin A/Cdk2 and p35-Cdk5 complexes
CC       and to a lesser extent by the cyclin D3/Cdk4 and cyclin B/Cdk1, in
CC       vitro. Dephosphorylated at Ser-368 by CDC14A and CDC14B around early
CC       anaphase. {ECO:0000269|PubMed:12697818, ECO:0000269|PubMed:17488717,
CC       ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:18332217}.
CC   -!- PTM: Acetylated by EP300; acetylation leads both to the decreased of
CC       SIRT2-mediated alpha-tubulin deacetylase activity and SIRT2-mediated
CC       down-regulation of TP53 transcriptional activity.
CC       {ECO:0000269|PubMed:18722353}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:12697818,
CC       ECO:0000269|PubMed:17516032}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Lacks deacetylase activity, at least toward
CC       known SIRT2 targets. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class I subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD45971.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF67015.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF083107; AAD40850.2; -; mRNA.
DR   EMBL; AF095714; AAD45971.1; ALT_INIT; mRNA.
DR   EMBL; AY030277; AAK51133.1; -; mRNA.
DR   EMBL; KF032391; AGZ02589.1; -; mRNA.
DR   EMBL; AJ505014; CAD43717.1; -; mRNA.
DR   EMBL; AF160214; AAF67015.1; ALT_FRAME; mRNA.
DR   EMBL; AK290716; BAF83405.1; -; mRNA.
DR   EMBL; AK314492; BAG37092.1; -; mRNA.
DR   EMBL; CH471126; EAW56833.1; -; Genomic_DNA.
DR   EMBL; CH471126; EAW56835.1; -; Genomic_DNA.
DR   EMBL; BC003012; AAH03012.1; -; mRNA.
DR   EMBL; BC003547; AAH03547.1; -; mRNA.
DR   EMBL; AF131800; AAD20046.1; -; mRNA.
DR   CCDS; CCDS12523.1; -. [Q8IXJ6-1]
DR   CCDS; CCDS46069.1; -. [Q8IXJ6-2]
DR   RefSeq; NP_001180215.1; NM_001193286.1.
DR   RefSeq; NP_036369.2; NM_012237.3. [Q8IXJ6-1]
DR   RefSeq; NP_085096.1; NM_030593.2. [Q8IXJ6-2]
DR   RefSeq; XP_006723174.1; XM_006723111.1. [Q8IXJ6-2]
DR   RefSeq; XP_011524956.1; XM_011526654.1. [Q8IXJ6-2]
DR   RefSeq; XP_011524957.1; XM_011526655.1. [Q8IXJ6-5]
DR   PDB; 1J8F; X-ray; 1.70 A; A/B/C=34-356.
DR   PDB; 3ZGO; X-ray; 1.63 A; A/B/C=34-356.
DR   PDB; 3ZGV; X-ray; 2.27 A; A/B=34-356.
DR   PDB; 4L3O; X-ray; 2.52 A; A/B/C/D=55-356.
DR   PDB; 4R8M; X-ray; 2.10 A; A/B=38-356.
DR   PDB; 4RMG; X-ray; 1.88 A; A=56-356.
DR   PDB; 4RMH; X-ray; 1.42 A; A=56-356.
DR   PDB; 4RMI; X-ray; 1.45 A; A=56-356.
DR   PDB; 4RMJ; X-ray; 1.87 A; A/B=56-356.
DR   PDB; 4X3O; X-ray; 1.50 A; A=52-355.
DR   PDB; 4X3P; X-ray; 1.80 A; A=52-355.
DR   PDB; 4Y6L; X-ray; 1.60 A; A/B=52-356.
DR   PDB; 4Y6O; X-ray; 1.60 A; A/B=52-356.
DR   PDB; 4Y6Q; X-ray; 1.90 A; A/B/C/D=52-356.
DR   PDB; 5D7O; X-ray; 1.63 A; A/B=50-356.
DR   PDB; 5D7P; X-ray; 1.76 A; A/B=56-356.
DR   PDB; 5D7Q; X-ray; 2.01 A; A/B=56-356.
DR   PDB; 5DY4; X-ray; 1.77 A; A=56-356.
DR   PDB; 5DY5; X-ray; 1.95 A; A=56-356.
DR   PDB; 5FYQ; X-ray; 3.00 A; A/B=1-356.
DR   PDB; 5G4C; X-ray; 2.10 A; A/B=34-356.
DR   PDB; 5MAR; X-ray; 1.89 A; A/B=56-356.
DR   PDB; 5MAT; X-ray; 2.07 A; A/C=56-356.
DR   PDB; 5Y0Z; X-ray; 2.00 A; A/B=52-356.
DR   PDB; 5Y5N; X-ray; 2.30 A; A=32-356.
DR   PDB; 5YQL; X-ray; 1.60 A; A=56-356.
DR   PDB; 5YQM; X-ray; 1.74 A; A=56-356.
DR   PDB; 5YQN; X-ray; 1.60 A; A=56-356.
DR   PDB; 5YQO; X-ray; 1.48 A; A=56-356.
DR   PDB; 6L65; X-ray; 1.80 A; A=50-355.
DR   PDB; 6L66; X-ray; 2.17 A; A=52-355.
DR   PDB; 6NR0; X-ray; 2.45 A; A/B=38-356.
DR   PDB; 6QCN; X-ray; 2.23 A; A/B=55-356.
DR   PDBsum; 1J8F; -.
DR   PDBsum; 3ZGO; -.
DR   PDBsum; 3ZGV; -.
DR   PDBsum; 4L3O; -.
DR   PDBsum; 4R8M; -.
DR   PDBsum; 4RMG; -.
DR   PDBsum; 4RMH; -.
DR   PDBsum; 4RMI; -.
DR   PDBsum; 4RMJ; -.
DR   PDBsum; 4X3O; -.
DR   PDBsum; 4X3P; -.
DR   PDBsum; 4Y6L; -.
DR   PDBsum; 4Y6O; -.
DR   PDBsum; 4Y6Q; -.
DR   PDBsum; 5D7O; -.
DR   PDBsum; 5D7P; -.
DR   PDBsum; 5D7Q; -.
DR   PDBsum; 5DY4; -.
DR   PDBsum; 5DY5; -.
DR   PDBsum; 5FYQ; -.
DR   PDBsum; 5G4C; -.
DR   PDBsum; 5MAR; -.
DR   PDBsum; 5MAT; -.
DR   PDBsum; 5Y0Z; -.
DR   PDBsum; 5Y5N; -.
DR   PDBsum; 5YQL; -.
DR   PDBsum; 5YQM; -.
DR   PDBsum; 5YQN; -.
DR   PDBsum; 5YQO; -.
DR   PDBsum; 6L65; -.
DR   PDBsum; 6L66; -.
DR   PDBsum; 6NR0; -.
DR   PDBsum; 6QCN; -.
DR   SMR; Q8IXJ6; -.
DR   BioGRID; 116593; 80.
DR   DIP; DIP-33350N; -.
DR   IntAct; Q8IXJ6; 48.
DR   MINT; Q8IXJ6; -.
DR   STRING; 9606.ENSP00000249396; -.
DR   BindingDB; Q8IXJ6; -.
DR   ChEMBL; CHEMBL4462; -.
DR   DrugBank; DB15493; Cambinol.
DR   DrugCentral; Q8IXJ6; -.
DR   GuidetoPHARMACOLOGY; 2708; -.
DR   iPTMnet; Q8IXJ6; -.
DR   PhosphoSitePlus; Q8IXJ6; -.
DR   BioMuta; SIRT2; -.
DR   DMDM; 38258608; -.
DR   EPD; Q8IXJ6; -.
DR   jPOST; Q8IXJ6; -.
DR   MassIVE; Q8IXJ6; -.
DR   MaxQB; Q8IXJ6; -.
DR   PaxDb; Q8IXJ6; -.
DR   PeptideAtlas; Q8IXJ6; -.
DR   PRIDE; Q8IXJ6; -.
DR   ProteomicsDB; 71008; -. [Q8IXJ6-1]
DR   ProteomicsDB; 71009; -. [Q8IXJ6-2]
DR   ProteomicsDB; 71010; -. [Q8IXJ6-3]
DR   ProteomicsDB; 71011; -. [Q8IXJ6-4]
DR   Antibodypedia; 2167; 563 antibodies.
DR   DNASU; 22933; -.
DR   Ensembl; ENST00000249396; ENSP00000249396; ENSG00000068903. [Q8IXJ6-1]
DR   Ensembl; ENST00000392081; ENSP00000375931; ENSG00000068903. [Q8IXJ6-2]
DR   Ensembl; ENST00000634533; ENSP00000489602; ENSG00000283100. [Q8IXJ6-1]
DR   Ensembl; ENST00000635478; ENSP00000488940; ENSG00000283100. [Q8IXJ6-2]
DR   GeneID; 22933; -.
DR   KEGG; hsa:22933; -.
DR   UCSC; uc002ojt.3; human. [Q8IXJ6-1]
DR   CTD; 22933; -.
DR   DisGeNET; 22933; -.
DR   GeneCards; SIRT2; -.
DR   HGNC; HGNC:10886; SIRT2.
DR   HPA; ENSG00000068903; Tissue enhanced (brain, skeletal muscle).
DR   MIM; 604480; gene.
DR   neXtProt; NX_Q8IXJ6; -.
DR   OpenTargets; ENSG00000068903; -.
DR   PharmGKB; PA35786; -.
DR   VEuPathDB; HostDB:ENSG00000068903.19; -.
DR   eggNOG; KOG2682; Eukaryota.
DR   GeneTree; ENSGT00940000157514; -.
DR   HOGENOM; CLU_023643_7_4_1; -.
DR   InParanoid; Q8IXJ6; -.
DR   OMA; FNMEKVG; -.
DR   OrthoDB; 973532at2759; -.
DR   PhylomeDB; Q8IXJ6; -.
DR   TreeFam; TF106181; -.
DR   PathwayCommons; Q8IXJ6; -.
DR   Reactome; R-HSA-2995383; Initiation of Nuclear Envelope (NE) Reformation.
DR   SABIO-RK; Q8IXJ6; -.
DR   SIGNOR; Q8IXJ6; -.
DR   BioGRID-ORCS; 22933; 9 hits in 1002 CRISPR screens.
DR   ChiTaRS; SIRT2; human.
DR   EvolutionaryTrace; Q8IXJ6; -.
DR   GeneWiki; SIRT2; -.
DR   GenomeRNAi; 22933; -.
DR   Pharos; Q8IXJ6; Tchem.
DR   PRO; PR:Q8IXJ6; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q8IXJ6; protein.
DR   Bgee; ENSG00000068903; Expressed in C1 segment of cervical spinal cord and 242 other tissues.
DR   ExpressionAtlas; Q8IXJ6; baseline and differential.
DR   Genevisible; Q8IXJ6; HS.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005677; C:chromatin silencing complex; NAS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:GOC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0097386; C:glial cell projection; ISS:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:UniProtKB-SubCell.
DR   GO; GO:0000792; C:heterochromatin; ISS:UniProtKB.
DR   GO; GO:0044224; C:juxtaparanode region of axon; ISS:UniProtKB.
DR   GO; GO:0043219; C:lateral loop; ISS:UniProtKB.
DR   GO; GO:0072687; C:meiotic spindle; ISS:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0033010; C:paranodal junction; ISS:UniProtKB.
DR   GO; GO:0033270; C:paranode region of axon; ISS:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0004407; F:histone deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IDA:GO_Central.
DR   GO; GO:0070403; F:NAD+ binding; IDA:UniProtKB.
DR   GO; GO:0017136; F:NAD-dependent histone deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0046970; F:NAD-dependent histone deacetylase activity (H4-K16 specific); IDA:UniProtKB.
DR   GO; GO:0034979; F:NAD-dependent protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0033558; F:protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0042903; F:tubulin deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0044242; P:cellular lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0061433; P:cellular response to caloric restriction; ISS:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; ISS:UniProtKB.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0071219; P:cellular response to molecule of bacterial origin; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0006342; P:chromatin silencing; NAS:UniProtKB.
DR   GO; GO:0006348; P:chromatin silencing at telomere; NAS:UniProtKB.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0016575; P:histone deacetylation; IDA:UniProtKB.
DR   GO; GO:0070932; P:histone H3 deacetylation; IMP:UniProtKB.
DR   GO; GO:0070933; P:histone H4 deacetylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007084; P:mitotic nuclear envelope reassembly; TAS:Reactome.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:1900425; P:negative regulation of defense response to bacterium; IMP:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:1900226; P:negative regulation of NLRP3 inflammasome complex assembly; IEA:Ensembl.
DR   GO; GO:0070446; P:negative regulation of oligodendrocyte progenitor proliferation; ISS:UniProtKB.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0061428; P:negative regulation of transcription from RNA polymerase II promoter in response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0034983; P:peptidyl-lysine deacetylation; IDA:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0051987; P:positive regulation of attachment of spindle microtubules to kinetochore; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB.
DR   GO; GO:0043388; P:positive regulation of DNA binding; ISS:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; ISS:UniProtKB.
DR   GO; GO:0045836; P:positive regulation of meiotic nuclear division; ISS:UniProtKB.
DR   GO; GO:1900195; P:positive regulation of oocyte maturation; ISS:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:2000777; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0006471; P:protein ADP-ribosylation; IDA:GO_Central.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0000183; P:rDNA heterochromatin assembly; NAS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0007096; P:regulation of exit from mitosis; NAS:UniProtKB.
DR   GO; GO:0031641; P:regulation of myelination; ISS:UniProtKB.
DR   GO; GO:0042325; P:regulation of phosphorylation; NAS:UniProtKB.
DR   GO; GO:0051775; P:response to redox state; NAS:UniProtKB.
DR   GO; GO:0021762; P:substantia nigra development; HEP:UniProtKB.
DR   GO; GO:0090042; P:tubulin deacetylation; IDA:UniProtKB.
DR   Gene3D; 3.30.1600.10; -; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR026591; Sirtuin_cat_small_dom_sf.
DR   InterPro; IPR017328; Sirtuin_class_I.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   Pfam; PF02146; SIR2; 1.
DR   PIRSF; PIRSF037938; SIR2_euk; 1.
DR   SUPFAM; SSF52467; SSF52467; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Autophagy; Cell cycle;
KW   Cell division; Cell membrane; Cell projection; Chromosome; Cytoplasm;
KW   Cytoskeleton; Differentiation; Immunity; Innate immunity; Meiosis;
KW   Membrane; Metal-binding; Microtubule; Mitosis; NAD; Neurodegeneration;
KW   Neurogenesis; Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..389
FT                   /note="NAD-dependent protein deacetylase sirtuin-2"
FT                   /id="PRO_0000110258"
FT   DOMAIN          65..340
FT                   /note="Deacetylase sirtuin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   NP_BIND         85..89
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25672491,
FT                   ECO:0007744|PDB:4RMG"
FT   NP_BIND         95..97
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25672491,
FT                   ECO:0007744|PDB:4RMG"
FT   NP_BIND         167..170
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25672491,
FT                   ECO:0007744|PDB:4RMG"
FT   NP_BIND         262..263
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25672491,
FT                   ECO:0007744|PDB:4RMG"
FT   NP_BIND         286..288
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25672491,
FT                   ECO:0007744|PDB:4RMG"
FT   REGION          116..120
FT                   /note="Peptide inhibitor binding"
FT   REGION          232..301
FT                   /note="Peptide inhibitor binding"
FT   MOTIF           41..51
FT                   /note="Nuclear export signal"
FT   ACT_SITE        187
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305"
FT   METAL           195
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236,
FT                   ECO:0000269|PubMed:11427894, ECO:0000269|PubMed:23454361,
FT                   ECO:0000269|PubMed:24389023, ECO:0000269|PubMed:25672491"
FT   METAL           200
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236,
FT                   ECO:0000269|PubMed:11427894, ECO:0000269|PubMed:23454361,
FT                   ECO:0000269|PubMed:24389023, ECO:0000269|PubMed:25672491"
FT   METAL           221
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236,
FT                   ECO:0000269|PubMed:11427894, ECO:0000269|PubMed:23454361,
FT                   ECO:0000269|PubMed:24389023, ECO:0000269|PubMed:25672491"
FT   METAL           224
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236,
FT                   ECO:0000269|PubMed:11427894, ECO:0000269|PubMed:23454361,
FT                   ECO:0000269|PubMed:24389023, ECO:0000269|PubMed:25672491"
FT   BINDING         324
FT                   /note="NAD; via amide nitrogen"
FT                   /evidence="ECO:0000269|PubMed:25672491,
FT                   ECO:0007744|PDB:4RMG"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         23
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         53
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5RJQ4"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5RJQ4"
FT   MOD_RES         207
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5RJQ4"
FT   MOD_RES         368
FT                   /note="Phosphoserine; by CDK2 and CDK5"
FT                   /evidence="ECO:0000269|PubMed:17488717,
FT                   ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:18332217,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         372
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   VAR_SEQ         1..38
FT                   /note="MAEPDPSHPLETQAGKVQEAQDSDSDSEGGAAGGEADM -> MPLAECPSCR
FT                   CLSSFRSV (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_008726"
FT   VAR_SEQ         1..37
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10393250,
FT                   ECO:0000303|PubMed:10931946, ECO:0000303|PubMed:12065666,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008724"
FT   VAR_SEQ         6..76
FT                   /note="PSHPLETQAGKVQEAQDSDSDSEGGAAGGEADMDFLRNLFSQTLSLGSQKER
FT                   LLDELTLEGVARYMQSERC -> R (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:24177535"
FT                   /id="VSP_055328"
FT   VAR_SEQ         266..271
FT                   /note="VQPFAS -> GRGLAG (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.10"
FT                   /id="VSP_008727"
FT   VAR_SEQ         272..389
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.10"
FT                   /id="VSP_008728"
FT   MUTAGEN         53
FT                   /note="S->A: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         97
FT                   /note="R->A: No effect on deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:11427894"
FT   MUTAGEN         98
FT                   /note="S->A: Inhibits deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         100
FT                   /note="S->A: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         116
FT                   /note="E->A: Reduces binding for the peptide inhibitor
FT                   S2iL5."
FT                   /evidence="ECO:0000269|PubMed:24389023"
FT   MUTAGEN         120
FT                   /note="E->A: Reduces binding for the peptide inhibitor
FT                   S2iL5."
FT                   /evidence="ECO:0000269|PubMed:24389023"
FT   MUTAGEN         167
FT                   /note="Q->A: Reduces deacetylase activity. Inhibits the
FT                   block of entry to chromosome condensation and subsequent
FT                   hyperploidy cell formation in response to mitotic stress;
FT                   when associated with A-168 and A-187."
FT                   /evidence="ECO:0000269|PubMed:11427894,
FT                   ECO:0000269|PubMed:16909107"
FT   MUTAGEN         168
FT                   /note="N->A: Abolishes deacetylation of alpha-tubulin.
FT                   Inhibits deacetylation of histone H3 at 'Lys-18'. Inhibits
FT                   the block of entry to chromosome condensation and
FT                   subsequent hyperploidy cell formation in response to
FT                   mitotic stress; when associated with A-167 and A-187."
FT                   /evidence="ECO:0000269|PubMed:11427894,
FT                   ECO:0000269|PubMed:12620231, ECO:0000269|PubMed:16909107,
FT                   ECO:0000269|PubMed:23908241, ECO:0000269|PubMed:24769394"
FT   MUTAGEN         170
FT                   /note="D->A,N: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:11427894"
FT   MUTAGEN         187
FT                   /note="H->Y,A: Inhibits deacetylase activity toward
FT                   histone, alpha-tubulin, FZR1 and CDC20. No effect on CDK2-
FT                   dependent phosphorylation. Does not inhibit interaction
FT                   with alpha-tubulin, HDAC6, HIF1A and the cyclin E-CDK2
FT                   complex. Inhibits interaction with BEX4 and KMT5A.
FT                   Abolishes deacetylation, dimeric formation and enzymatic
FT                   activity increase of G6PD. Prevents histone H4 methylation
FT                   at 'Lys-20'(H4K20me1) in metaphase chromosomes. Inhibits
FT                   the block of entry to chromosome condensation and
FT                   subsequent hyperploidy cell formation in response to
FT                   mitotic stress; when associated with A-167 and A-168."
FT                   /evidence="ECO:0000269|PubMed:10381378,
FT                   ECO:0000269|PubMed:11427894, ECO:0000269|PubMed:11812793,
FT                   ECO:0000269|PubMed:12620231, ECO:0000269|PubMed:12697818,
FT                   ECO:0000269|PubMed:16909107, ECO:0000269|PubMed:17488717,
FT                   ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:17726514,
FT                   ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:24681946,
FT                   ECO:0000269|PubMed:27512957"
FT   MUTAGEN         244
FT                   /note="F->A: Reduces strongly binding for the peptide
FT                   inhibitor S2iL5."
FT                   /evidence="ECO:0000269|PubMed:24389023"
FT   MUTAGEN         265
FT                   /note="Q->A: Reduces binding for the peptide inhibitor
FT                   S2iL5."
FT                   /evidence="ECO:0000269|PubMed:24389023"
FT   MUTAGEN         271
FT                   /note="S->A: Reduces binding for the peptide inhibitor
FT                   S2iL5."
FT                   /evidence="ECO:0000269|PubMed:24389023"
FT   MUTAGEN         279
FT                   /note="S->A: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         280
FT                   /note="T->A: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         294
FT                   /note="D->A: Reduces binding for the peptide inhibitor
FT                   S2iL5."
FT                   /evidence="ECO:0000269|PubMed:24389023"
FT   MUTAGEN         311
FT                   /note="S->A: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         315
FT                   /note="Y->A: Reduces deacetylase activity."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         364
FT                   /note="S->A: Abolishes CDK2-dependent phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   MUTAGEN         368
FT                   /note="S->A: Does not affect deacetylase activity.
FT                   Abolishes CDK2-dependent phosphorylation. Inhibits cellular
FT                   proliferation delay in the early metaphase to prevent
FT                   chromosomal instability. Does not inhibit interaction with
FT                   a cyclin E-CDK2 complex. Does not inhibit interaction with
FT                   HDAC6 and ubiquitination. Inhibits cell adhesion and
FT                   migration and neurite outgrowth. Inhibits deacetylase
FT                   activity; when associated with A-372."
FT                   /evidence="ECO:0000269|PubMed:17488717,
FT                   ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:18332217"
FT   MUTAGEN         368
FT                   /note="S->D: Abolishes CDK2-dependent phosphorylation.
FT                   Inhibits interaction with a cyclin E-CDK2 complex. Reduces
FT                   strongly histone deacetylation activity."
FT                   /evidence="ECO:0000269|PubMed:17488717,
FT                   ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:18332217"
FT   MUTAGEN         368
FT                   /note="S->E: Abolishes CDK2-dependent phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17488717,
FT                   ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:18332217"
FT   MUTAGEN         372
FT                   /note="S->A: Reduces phosphorylation. Does not inhibit
FT                   interaction with HDAC6, ubiquitination and deacetylase
FT                   activity. Inhibits deacetylase activity; when associated
FT                   with A-368."
FT                   /evidence="ECO:0000269|PubMed:17516032"
FT   CONFLICT        199
FT                   /note="S -> N (in Ref. 6)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        219
FT                   /note="P -> L (in Ref. 5; CAD43717)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..45
FT                   /evidence="ECO:0007744|PDB:3ZGO"
FT   STRAND          60..63
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           64..71
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          73..75
FT                   /evidence="ECO:0007744|PDB:3ZGV"
FT   STRAND          79..83
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           85..87
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           89..91
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          96..98
FT                   /evidence="ECO:0007744|PDB:4RMI"
FT   HELIX           99..101
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           103..105
FT                   /evidence="ECO:0007744|PDB:4X3O"
FT   HELIX           108..110
FT                   /evidence="ECO:0007744|PDB:4X3O"
FT   HELIX           115..119
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           121..126
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           129..138
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          139..142
FT                   /evidence="ECO:0007744|PDB:3ZGO"
FT   HELIX           147..157
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          161..166
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           172..175
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           180..182
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          183..185
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          188..196
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   TURN            198..200
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          203..205
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           206..215
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   TURN            222..224
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          227..232
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           241..250
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   TURN            251..253
FT                   /evidence="ECO:0007744|PDB:4RMI"
FT   STRAND          255..261
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          264..266
FT                   /evidence="ECO:0007744|PDB:5Y0Z"
FT   HELIX           269..275
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          282..288
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   TURN            295..297
FT                   /evidence="ECO:0007744|PDB:4X3O"
FT   HELIX           301..303
FT                   /evidence="ECO:0007744|PDB:5DY4"
FT   STRAND          309..311
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   STRAND          316..322
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           324..334
FT                   /evidence="ECO:0007744|PDB:4RMH"
FT   HELIX           338..353
FT                   /evidence="ECO:0007744|PDB:4RMH"
SQ   SEQUENCE   389 AA;  43182 MW;  A392442A8F6316F1 CRC64;
     MAEPDPSHPL ETQAGKVQEA QDSDSDSEGG AAGGEADMDF LRNLFSQTLS LGSQKERLLD
     ELTLEGVARY MQSERCRRVI CLVGAGISTS AGIPDFRSPS TGLYDNLEKY HLPYPEAIFE
     ISYFKKHPEP FFALAKELYP GQFKPTICHY FMRLLKDKGL LLRCYTQNID TLERIAGLEQ
     EDLVEAHGTF YTSHCVSASC RHEYPLSWMK EKIFSEVTPK CEDCQSLVKP DIVFFGESLP
     ARFFSCMQSD FLKVDLLLVM GTSLQVQPFA SLISKAPLST PRLLINKEKA GQSDPFLGMI
     MGLGGGMDFD SKKAYRDVAW LGECDQGCLA LAELLGWKKE LEDLVRREHA SIDAQSGAGV
     PNPSTSASPK KSPPPAKDEA RTTEREKPQ
//
